Increasing evidence exists that cancer is associated with abnormalities in gene regulation expressed in multiple molecules at the cell surface membranes. Abnormal gene regulation may direct a blockage or a deviation in synthesis and organization of cell surface molecules that mediate cellular interaction, development, and differentiation (1, 2) . Classical enzymology found a parallelism in enzyme deviation, particularly in its isozyme pattern, between cancer and embryonic tissues (3); and classical immunology recognized an antigenic similarity between these two counterparts (4) . A similarity between leukemic antigens and those in stem cells has been emphasized, and an apparent specific antigen in leukemia cells appears to be predominantly normal differentiation antigen (5) . The idea of "oncofetal" or "oncodifferentiation" expression of cell surface molecules has been further endorsed by tumor-associated and differentiation-dependent changes of a chemically well-defined class of membrane molecules called "glycosphingolipids" (or glycolipids). Studies along this line have been greatly catalyzed by a few technologic revolutions: a) separation of membrane glycosphingolipids on high-performance chromatography and structural analysis based on methylation, mass spectrometry, and enzymatic degradation (6, 7); b) hybridoma technique for production of monoclonal antibodies (8) ; and c) immunostaining of glycolipids separated on TLC (9) .
The chemical quantity and organization of glycolipids in membranes and their reactivity to specific ligands are not only defined according to their genetic background but also are under epigenetic control and vary according to cell cycle and cell contact; their overall expression reflects the stage of differentiation and oncogenic transformation. Recently, many new glycolipids have been discovered (2, 10) by improved techniques in separation and structural characterization. Accordingly, the glycolipid pattern of some transformed cells or tumors, previously described, should be reevaluated by new analytic techniques. Designation of glycolipids used in this paper and their structures are shown in table 1 .
Dramatic changes in glycolipid composition and metabolism have been observed not only in virally or chemically transformed cells but also in spontaneous tumors, including a large variety of human cancers. Since this phenomenon was first observed in virally transformed cells by us (12) and by Brady and his associates (13) in 1968-69, an extensive number of studies have been focused on this topic; consequently, the specific role of glycolipids in defining oncogenic membrane phenotype has been sought. The early efforts on this topic were extensively reviewed in (14-16) and will not be detailed here. This review will focus on a few recently developed topics as follows: 1) chemistry of tumor-associated and developmentally regulated glycolipid markers, 2) factors affecting glycolipid expression at the cell surface, and 3) possible application of glycolipid markers in treatment and diagnosis of human cancer.
TYPES OF GLYCOLIPID CHANGES IN TUMORS
Since each type of cell has a specific profile of glycolipid composition, the change of glycolipids after transformation in each type of cell differs greatly, often as a result of ABBREVIATIONS USED: 7 CEA=carcinoembryonic antigen(s); Cer=ceram-ide(s); EBV=Epstein-Barr virus; FAA=N-(2-l1uorenyl)acetamide; Gal= galactose; Fuc=fucose (S-deoxy-r-Gal); GaINAc-=N-acetylgalactosamine; GD=GD ,• or GD lb; GIc=glucosyl; GIcNAc-N-acetylglucosamine; GM,=GM ,• or GM,b; GT=GT ,• or GT,b; Hex=hexosyl (hexose); HexN=hexosaminyl (hexosamine); HSV=hamster sarcoma virus; KiMuSV=Kirsten strain of murine sarcoma virus; NeuAc=N-acetylneuraminic acid (one type of sialic acid); py=polyomavirus; R=residue of chemical functional group; RSV=Rous sarcoma virus; SA=sialic acid (NeuAc or N-glycolylneuraminic); SV 4O=simian virus 40; TLC=thin-layer chromatography; ts=temperature sensitive (temperature-sensitive); VSV=vesicular stomatitis virus. 
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GDa--/I----+GD,a, GD ,b, GT 'b 35- 37 27 developmental arrest or regression. The following types of changes are discussed: 1) incomplete synthesis; 2) neosynthesis, including a shifting of glycolipid synthesis from one series to another; 3) loss of "contact response"; and 4) organizational changes. A combination of these mechanisms may occur in vivo to give the total effect of glycolipid changes that behave as tumor-associated markers. Different combinations of these mechanisms may account for pleomorphic tumor phenotypes.
Blocked Synthesis
In early investigations, cultured fibroblasts and their viral transformants were compared for their glycolipid composition in which a relatively simple pattern was demonstrated, i.e., incomplete synthesis of higher glycolipids (12, 17-19) due to a block of a single and/or multiple glycosyl transferase (13, (17) (18) (19) (20) (21) (22) 23) . Typical examples including GM3 in hamster BHK-21 cells; Gb3, Gb4, and Gbs in NIL cells; higher gangliosides (GO, GT) in mouse fibroblasts; and others are shown in table 2. For spontaneous tumors and human cancers, comparable normal cells or tissues are unavailable; nevertheless, the glycolipid composition of human leukemia leukocytes (24, 25) , brain tumors (26, 27) , kidney tumors (28) , and gastrointestinal cancer (29) was studied in comparison with that of "normal" cells and tissues. The results indicate that blocked synthesis and precursor accumulation may indeed be occurring in these human cancers as well.
Neosynthesis
Synthesis of glycolipids unique to the tumor (neosynthesis) has often been found in many human cancers and in spontaneous tumors resulting in "neoglycolipids" (tables 3, 4) . The increasingly known case of neoglycolipids will become more common through studies with monoclonal antibody approach. Some tumors display a combination of blocked synthesis and neosynthesis; therefore, the patterns of glycolipid changes are highly diverse. Incomplete synthesis of glycolipids often accompanies accumulation of precursor glycolipid. LacCer accumulation in some BHK tumor cells transformed by py (12), as well as GM2 and Gg3 (asialo GM2) in BALB/c mouse 3T3 tumor cells transformed by KiMuSV (39) , are typical examples (table 3) . However, recent studies indicate that Gg3 accumulation in BALB/c mouse 3T3 tumor cells transformed by KiMuSV is due to an enhanced synthesis of Gg3 in addition to a blocked synthesis of GMI (60) ; therefore, the distinction between precursor accumulation and neosynthesis is sometimes unclear. 
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Shifting of Glycolipid Synthesis From One Series to Another
Each type of cell or cell line is defined by a characteristic composition of three series of glycolipid: globo, lacto, and ganglio series (table I) . One type of cell is usually characterized by a predominance of one series of glycolipids, while other types of cells have the second minor series. A shifting of glycolipid synthesis from one series to another can be seen upon oncogenic transformation. Nontransformed NIL cells had three components of the globo series: Gb3, Gb 4 , and Gb 5 ; NIL cells transformed by py were characterized by a reduction of all three globo components and by a neosynthesis of lacto series nLc4 (53) . Normal myelocytes were characterized by the major component nLc4; in contrast, myelomonoblastic leukemia cells contained about equal quantities of nLc4 and Gb 4 (25) . In both cases, glycolipid synthesis of one series shifted to another series upon oncogenic transformation. This type of shifting is also obviously associated with expression of malignancy degrees (61, 62) and with differentiation (see "Developmentally Regulated Glycolipid Markers and Their Anachronistic Expression in Tumors").
Loss of "Contact Response" in Glycolipid Synthesis
The chemical concentration and overall synthesis of glycolipids in nontransformed NIL or BHK-21 cells were significantly higher in nongrowing confluent culture as compared to those in actively growing cells in sparse culture (19) (20) (21) . The glycolipid response, designated contact response of glycolipid synthesis, was lost when cells were transformed with py or HSV (20, 22) and by chemical carcinogens (33) . The contact response ofa-galactosyl transferase for synthesis of Gb3 was demonstrated in cell-free extract of confluent NIL cells, and the response was lost in py-transformed NIL cells (23) . The contact response was remarkable at the touching phase of mouse 3T3 Swiss albino mouse cell culture as compared to that for confluent culture, JNCI, VOL. 71, NO.2, and the response was lost in transformed 3T3 cells (63) . The mechanism of this phenomenon remains intriguing for further studies, but it may be closely related to contact inhibition of cell growth (21) , and the loss of contact response in py-transformed NIL cells was partially related to tumorigenicity (64) .
Change of Glycolipid Organization in Membranes
Glycolipids alter not only their chemical composition and metabolism but also their state of organization in membranes associated with oncogenic transformation (18, 53, 65) . In many transformed cells, glycolipids in membranes become more exposed or more accessible to exogenous ligands. Cell cycle-dependent changes of glycolipid exposure are also altered in transformed cells as compared to those in nontransformed counterparts (53, 65, 66, 67) ; see "Factors Affecting Glycolipid Expression at the Cell Surface."
TRANSFORMING GENE, TUMORIGENESIS, TUMOR PROMOTOR, AND GLYCOLIPID CHANGES Glycolipid Changes-a Consequence of Transforming Gene Activation?
The idea that glycolipid change is closely related to the expression of transforming genes has been supported by the reversible GM 3 synthesis in chick embryonic fibroblast infected with ts mutants of RSV (68) and in BHK-21 cells infected with a ts mutant of py (69) . In such a system the transformed phenotype is expressed at permissive temperature (30-32°C), and the phenotype disappears at nonpermissive temperature (39-40°C) . Genetic analysis of the RSV and its ts mutant clearly indicated that the transforming gene (STC) is activated at permissive temperature and is inactivated at nonpermissive temperature (70) . The STC gene product was identified as a protein kinase with a molecular weight of 60,000 (p60"rc) (71) . Although the chemical property and function of the substrate for p60"rc have not been fully identified, the substrate could initiate a series of cascade reactions leading to various changes in membrane structure and function. A reasonable assumption is that the change of GM3 in chick embryonic fibroblast is triggered by the activation of p60 8rC ; however, the GM3 change occurred during a lapse of 24-48 hours after, but not immediately after, infection with wild-type tumor virus, or the infected cells with the ts mutants of the tumor virus were exposed to the permissive temperature (68) . Other changes, e.g., cytoskeletal organization, sugar transport, deletion of fibronectin, precede the event of the GM3 change. Thus glycolipid change may occur as one of the latest events as a consequence of transforming gene activation; nevertheless. the change seems to be triggered by the src gene activation.
Recently, more than 20 oncogenes ofanimal tumor viruses have been characterized. Each oncogene codes a specific protein or proteins with different functions; some of them show protein kinase activity, some bind GTP, and the functions of others are unidentified. Their intracellular localization and mode of expression are highly diverse. Thus heterogeneity of oncogenes and variation in their mode of expression have become increasingly apparent (73, 74) . The pp60 of src, p21 of ras, p80 of ros, and p120 of abl represent only a few examples (74) . Furthermore, hybridization experiments indicate that homology of more than 15 animal oncogenes has been detected in a large variety of human cancer and normal cells, although the level of oncogene homology in normal cells is very low. Transfection experiments with cellular DNA's have demonstrated that both normal and transformed cells contain genes capable of inducing oncogenic transformation. DNA's of a variety of tumors from several different species, including humans (e.g., bladder cancer), are capable of inducing transformation of 3T3-Swiss albino (NIH) mouse cells with high efficiencies (75) . These experiments indicate that oncogenic transformation can involve dominant genetic alteration resulting in the activation of cellular transforming genes (76) . In exceptional cases, transformed cells showed an identical glycolipid pattern as their progenitors (64, 77) but differed in contact response of GM3 synthesis (64) . Thus a logical assumption is that a high degree of variation in glycolipid composition, organization, and synthesis in experimental animal and human tumor cells may reflect high variation of a transforming gene and its mode of expression. Glycolipid changes were also demonstrated in ts mutants of chemically transformed cells at permissive temperature (78) , which suggests a cellular transforming gene mutated by a chemical carcinogen to be ts. Expression of a mutant gene may include altered glycolipid synthesis.
Glycolipid Changes-Any Relation to Tumorigenicity and Metastatic Property?
No definitive information is available on whether glycolipids playa functional role in defining tumorigenicity and metastatic property. However, a difference in glycolipid composition was observed among cells with different tumorigenicity, i.e., the high-and/or low-tumorigenic hybrids of Klein and co-workers (79) . The low tumorigenic hybrids resulting from a fusion between high-and low-tumorigenic
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cells in which tumorigenicity was suppressed (79) showed a higher content of GM 3 and long-chain neutral glycolipids but low levels of GD or GT gangliosides (72) . The hightumorigenic hybrids resulting from a fusion between two high-tumorigenic variants showed, in general, a low GM3 content and a high level of GD or GT ganglioside (72) . Interestingly, a low GM 3 content was also correlated with a highly malignant "free-form" ascites hepatoma, whereas a high GM 3 content was found in the less malignant adhesiveform ("island form") hepatoma (61) . The tumorigenicity of NIL cell variants has been correlated with the absence of cell density-dependent response ofGM3 synthesis with, however, a few exceptions (64) . Yogeeswaran and associates (80, 81) claimed that metastatic property ofB16 melanoma and 3T3 sarcoma cells induced by KiMuSV showed a correlation with glycolipid composition and organization. The highly metastatic melanoma showed a loss of GM3 crypticity and an enhanced level of GT or GD ganglioside (80) , and a highly metastatic KiMuSV-induced sarcoma showed a high level of and greater exposure of Gg3 and a high level of GT or GD ganglioside (81) . The degrees of sialylation in glycolipids and in glycoproteins were claimed to be closely related to the degrees of metastatic property (82) .
Glycolipid Changes in Precancerous State and Those Induced by Tumor Promoter and Inhibitors
Changes in glycolipid composition and synthesis are not only remarkable in established tumors but also in precancerous hyperplastic and/or dysplastic lesions. Changes in blood group hapten have been known in precancerous dysplastic oral epithelia (83) , in precancerous gastric mucosae (84) , and in fucogangliosides in precancerous rat liver (42) . The ganglioside changes in precancerous hyperplastic nodules induced in rat liver by feeding the chemical carcinogen FAA were extensively studied. Although blocked synthesis from GD to GT was observed, a stage-specific enhancement of GM3, GM2, and GMl synthesis was observed at different stages of the precancerous process. There was a clear distinction between two synthetic pathways, i.e., monosialo and disialo pathways during the process of carcinogenesis; however, a blocked synthesis of GTlb from GDlb was eventually observed in hepatoma (35, 36) . During the course of a similar process as above, two types of fucolipids were found to be accumulated in precancerous rat liver before development of hepatoma. One is FucGM l and the other, Fuc(aGal)GM l (see tables 1, 4). Both fucogangliosides persisted in hepatoma in vivo, and FucGM l persisted in hepatoma cell lines in vitro. Both fucolipids were undetectable in normal rat liver as well as in livers of rats fed nonhepatic carcinogen (42) . Consequently, the enzymatic basis of this phenomenon was studied. An a-fucosyl transferase specific to GM l or Gg 4 was absent in normal rat liver but clearly detectable in livers of rats fed FAA. The same enzyme activity in the established rat hepatoma cells was fifteenfold to fortyfold higher. However, a-galactosyl transferase is consistently present in normal rat liver as well as in livers of rats fed with chemical carcinogen (85) . Thus the accumulation of these fucolipids in precancerous liver and in hepatoma is crucially determined by induction of an a-fucosyl transferase (text- fig. 1 ).
c( Fuc transferase
Glycolipid Markers for Experimental Animal Cancers (Table 4) branes may enhance the exposure of a specific type of glycolipid at the cell surface, which may also contribute to the expression of a tumor-specific cell surface marker. Blocked synthesis of glycolipid in tumors often accompanies an accumulation of its precursor, and neosynthesis results in the appearance of a new glycolipid. Either mechanism induces an accumulation of a glycolipid characteristic of tumor cells but absent or present in small quantities in nontransformed progenitor cells. These glycolipid tumor markers are hardly immunogenic to the host and are shared with various types of tumors; they are therefore distinctive from classical "tumor-associated antigen," and the term "tumor marker" is more appropriate. Their presence has been determined through systematic chemical analysis of tumors and normal cells and tissues. Most of the glycolipid markers as shown in table 4 were discovered by such a comparative chemical analysis. Recently, their presence has been increasingly clear through studies with monoclonal antibodies. In addition, organizational changes in memRecently, Srinivas and Colburn (86) observed that synthesis of GT and a slower migrating unknown ganglioside in JB6 mouse epidermal cells was suppressed in the presence of tumor promoter phorbol esters but not suppressed by nonpromoters. The ganglioside response to the tumor promoter was antagonized by the antipromoter retinoic acid (86) . The decrease of GT induced by the tumor promoter was associated with the manifestation of tumor cell phenotype (such as anchorage independence and tumorigenicity); however, the insertion of GT ganglioside exogenously into the promoter-treated cells prevented the appearance of tumor cell phenotype as measured by anchorage-independent cell growth. The nonpromotable variant (phorbol ester-resistant "R" lines) did not decrease GT synthesis upon addition of promoter (87) . Retinoids, the antipromoter, showed a remarkable effect on cellular glycolipids. Ganglioside synthesis and its contact response in transformed NIL and 3T3 cells became similar to those of "normal cells" when cell growth was inhibited and contact inhibitability was induced by retinoic acid (88) . These works clearly indicate the important role a specific ganglioside plays in the process of tumor promotion and growth regulation. Ganglioside may regulate the receptor function for the tumor promotor analogous to growth factor receptor (89) .
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Human Cancer Markers Defined by Monoclonal Antibodies (Tables 5, 6)
Biochemical properties of tumor-associated antigens have been increasingly revealed by application of hybridoma technology established by Kohler and Milstein (8) . More than a few glycolipids have been identified as tumor-associated markers defined by monoclonal antibodies, although their biologic significance is unknown.
In recent years, some evidence indicated that some glycolipids of transformed cells are unique and distinctive from those in normal progeniter cells. The same glycolipid should not be expressed at the surface of other normal cells and tissues. The presence of nLc4 in hamster NIL tumors transformed by py and its absence in normal hamster fibroblast NIL or BHK was the first example (53) . The py-transformed NIL tumors grown in hamsters contained this glycolipid in significant quantity. Interestingly, antibody response to this glycolipid was observed in hamsters bearing py-transformed NIL tumors (90) .
BALB/c mouse tumors that arose from inoculation of 3T3 cells transformed by KiMuSV (39) , as well as mouse lymphoma L5178 in DBA/2 mice (40), contained much Gg a . Various organs of BALB/c or DBA/2 mice did not contain appreciable quantities of this glycolipid. This glycolipid, therefore, can be regarded as a tumor-associated cell surface marker (39, 40) and was found to be useful in immunotherapy with monoclonal antibodies directed to this glycolipid (see "Diagnostic and Therapeutic Implications of Glycolipid Changes Associated With Cancer"). Much Ggs, Gg 4 , and fucosyl Gg 4 have been found in highly malignant ascites hepatoma (61); these could be tumor-associated markers.
VSV obtained from the SV40-transformed hamster cell line acquires a tumor-specific transplantation antigen activity that causes rejection of SV40-transformed tumor. A polar glycolipid fraction prepared from VSV from SV 40-transformed tumor, this fraction being incorporated into liposomes, was shown to be immunogenic and capable of suppressing growth of the SV 40-transformed tumor. Antiserum directed to liposomes containing the polar glycolipids of SV40-transformed hamster tumor cells, after being absorbed with normal hamster tissue, specifically reacts with the SV40-transformed cells (91, 92) . These results imply that a specific glycolipid acts as an SV40-induced antigen in hamster cells. In these studies, however, a pure glycolipid was neither isolated nor characterized. Since the amphipathic polypeptides can be associated and copurified with a polar glycolipid fraction, and such polypeptides can be highly immunogenic (93) , great care is needed to distinguish glycolipid and amphipathic polypeptides present in glycolipid fraction. Gal,8l->4GlcNAcf3l->3Gal,8l->4GlcNAcf3l->3Gal,8l->4Glcf3l->lCer 3 3 i i
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Glycolipid Antigens of Colorectoadenocarcinomas
Several monoclonal antibodies directed to colorectoadenocarcinomas have been prepared by Koprowski et al. (94) . Four monoclonal antibodies produced by hybridomas obtained from a mouse immunized with a human adenocarcinoma cell line, SW1116, have been characterized as being directed to Le b structure (98) . An apparent specificity of antibody for the colorectoadenocarcinoma cell line described by Koprowski et al. (94) may reflect the high concentration of Lea and Le b glycolipids that coexist in some adenocarcinomas (99) . In contrast, normal human intestine contains exclusively either Lea or Le b glycolipid, displaying the same Lewis status as erythrocytes (100) . Some gastric cancer contains much Lea glycolipid, although normal gastric mucosa contains both Lea and Le b glycolipids (101). The hybridoma antibody N-19-9 was found to be highly specific not only for colorectoadenocarcinoma but also for gastric and pancreas cancer. The binding of the antibody to carcinoma tissue extract was inhibited by sera from patients with adenocarcinoma of the colon but not by sera from patients with other bowel diseases or from healthy volunteers (52) . However, the antibodies stained limited loci of glandular epithelia of normal pancreas and gastric mucosae (102) . The specific antigen defined by this monoclonal antibody was found in the ganglioside fraction of tumor and meconium and was identified as monosialoganglioside (9) . The structure of the antigen was recently determined as sialosyl Lea by Magnani et al. (51) (table 5). Sialylated type 1 chain has not been reported in normal tissues. Thus the synthesis of sialosyl Lea structure must be specifically enhanced in tumor cells. The glycolipid with sialosyl-X-structure was previously isolated from normal human kidney by Rauvala (103) . Whether synthesis of this structure is enhanced in cancer is worthy of study.
Monoclonal Antibodies Directed to the Carbohydrate Sequence X (Gal/31-+4[Fuca1-+3jGlcNAc), Showing an Apparent Tumor Specificity
One hybridoma antibody (WGHS 29-1), which resulted from immunization with gastric cancer cells, and three hybridoma antibodies (ZWG 13, ZWG 14, ZWG 111), which resulted from immunization with cells from a liver metastasis of a colon adenocarcinoma, were found to be directed to X-structure (Galpl-+4[Fucal-+3]GlcNAc) (45) . The embryonic antigen SSEA-l, defined by its monoclonal antibody has been identified as X-structure (46, 104) , although SSEA-l antibody does not react well in a solid-phase ra- NeuAca2->8NeuAca2->3Galf3l->4Glcf3l->lCer (Cer contained C20-24 fatty acids) (6, 38)a
a No reaction with GT 1a or GQlb, which have the same terminus as GD a , i.e., NeuAca2->8NeuAca2->3Gal,8l->R (see table 1 ). dioimmunoassay with lactofucopentaosyl(III)Cer (46) under the same conditions that allow it to react with the Xstructure carried by a long type 2 chain, i.e., fucosyl lactonorhexaosyl or lactonoroctaosyl, including such structuresasY2, ZI, and Z2a (?fane of the antibodies (WGHS-29) reacts with lactofucopentaosyl(III)Cer better than other X-structures that have longer carbohydrate chains (45) . Another set of monoclonal antibodies was produced by hybridomas obtained from mice immunized with a human lung cancer cell line (small cell carcinoma), which have an apparent specificity for human small cell carcinoma, adenocarcinoma, and squamatous carcinoma of lung (105). These antibodies have been identified also as having an apparent specificity for X-structure (47) . The monoclonal antibodies all react with a series of glycolipids accumulated in various lung cancer tissues. The major glycolipid reacting to these antibodies had the same TLC mobility as lactofucopentaosyl(III)Cer (47) first found to be accumulated in some, if not all, human adenocarcinomas (48) . Other slower migrating glycolipids from lung tumors, detected by these antibodies on TLC, may include difucosylated or trifucosylated derivatives.
Recently, a systematic study on the X-hapten glycolipids of normal and tumor tissue has been undertaken (7, 46, 49) .
The presence of an unusual difucosylated or trifucosylated polylactosamine glycolipid accumulating in a large variety of human adenocarcinomas has been particularly noticeable (table 5) . Six structures with X-determinant have been identified. Glycolipids having a common structure as shown below (formulas A, B) accumulate in large quantities in many cases of human adenocarcinoma, including colon, gastric, lung, and liver cancer.
However, glycolipids with X-determinant at the terminus of a long type 2 chain as shown below (formula C) are also present in normal tissues and are not necessarily specific for tumor tissue (49) .
It is possible that a specific fucosyl transferase for synthesis of the fucosyl residue (I), (II) in formulas A and B could be greatly enhanced in various human adenocarcinomas. In contrast, a fucosyl transferase for synthesis of fucosyl residue (III) may not be affected by cancer. So far, all monoclonal antibodies directed to X are directed to the terminal structure in C. If we could select an antibody directed to the difucosyl or polyfucosyl structure in B or its analogue, such an antibody may have higher specificity to human adenocarcinoma. Recently, a monoclonal antibody directed to sialosyla2-6galactosyl residue of gangliosides was established. This antibody defines a few gangliosides containing the terminal structure as defined above. A novel ganglioside that is present in colon cancer and hepatoma but absent in normal colon mucosa and liver has been isolated and its structure was characterized as shown in table 5 (item C) (129) .
Melanoma Antigen
Two monoclonal antibodies specifically directed to human melanoma cells have been identified as being directed to a glycolipid (95, 96) . The antigen defined by IgG3 antibody (R24) (95) was identified as a ganglioside with the same TLC mobility and carbohydrate composition as GOa ganglioside (38) . The antigen specifically reacting to IgM antibody (4.2 antibody) (96) was characterized by methylation and enzymatic degradation as GOa (table 6) . In contrast to brain GOa ganglioside, melanoma GOa contained a much higher proportion of long-chain fatty acids, C22 and C24. The 4.2 antibody did not react with various other gangliosides including GTla and GQIb, which had the same terminal sequence as GOa, i.e., NeuAca2-8NeuAca2-3Gal (6) . GOa ganglioside is known to be present in small quantities in brain and in various other tissues and organs. A relative abundance of this glycolipid in retina (106) and kidney (107) has been known. Nevertheless, the reactivity of the antibody to various tissues including kidney was highly restricted, although the reactivity of the antibody to retina has not been tested. Normal melanocytes and nevus did not show the reactivity. An association of GOa with human melanoma was previously claimed by Portoukalian et al. (50) . The apparent melanoma specificity of GOa gangliosides could be due to their very high concentration and also to a specific organization of GOa at the melanoma cell surface.
Burkitt's Lymphoma Antigen
A hybridoma secreting a rat monoclonal IgM antibody directed to Burkitt's lymphoma (Daudi) was established (97) . This antibody defined an antigen specifically expressed on Burkitt's tumor cells irrespective of their possessing EBV genome. The antigen was not detectable on an EBV-positive lymphoblastoid cell line, mitogen-activated lymphocytes, or fresh malignant cells from patients affected with various lymphoproliferative disorders (97) . The antigen was identified as simple Gba; Galal-4Gal,81-4Glc,l1l-ICer (41), its structure established in 1971 (108). Upon chemical analysis, only Burkitt's lymphoma cell lines had much of this glycolipid (200-800 p.g/1O mg cell residue). However, a small quantity of this glycolipid is widely distributed in various tissues and cells. Human erythrocytes have this glycolipid in a moderate amount (5-10 p.g/1O mg) (109), but erythrocytes were not reactive to anti-p k antibodies (110). In a very rare genetic (blood group pk individuals) trait, the chemical quantity of this glycolipid in erythrocytes was many times higher than normal; therefore pk erythro- Glycoprotein from both cases showed I (Step) and i (MeDon) activity, whereas one case displayed I (Ma) activity. Subsequent immunohistochemical studies (84) indicated that Ii reactivity of mucosae is closely related to secretor and/or nonsecretor status in addition to cancer; i.e., most carcinomas from secretors showed foci of substantial staining with anti-I (Ma) in contrast to normal secretor mucosae that had no staining with anti-I (Ma). This is probably due to incomplete synthesis of A/H determinants. No substantial staining with anti-I (Ma) was observed in nonsecretor mucosae or in nonsecretor tumor.
A well-organized pattern of carbohydrate architecture in normal oral mucosae (130) is disarranged, i.e., dislocation of H-antigen and loss of A-antigen is obvious in the spinous layer of dysplastic mucosae (83) .
Incomplete synthesis of blood group ABH antigen with type 1 chain may result in accumulation of other specificity unrelated to Ii. Recently, a case of bronchogenic lung cancer with an incidental gammopathy was reported (125) . The serum of the patient was found to contain a monoclonal warm-reactive IgM (designated IgMWj which was shown to react with lactotetraosyl structure (GalfJl-+3Glc-NAcfJl-+3GalfJl-+R). The specificity is not directed to Ii determinant, whereas this antibody was directed to type 1 chain precursor. The lung cancer was regressed presumably because the patient had a concurrent gammopathy, although the patient also had received X-ray therapy. One interpretation was that concurrent warm-reactive IgM directed to the type 1 chain precursor suppressed the tumor growth, since the corresponding antigen structure could be accumulated in this tumor.
cytes react very well with anti-p k antibodies, although normal human erythrocytes with PI or P2 populations react poorly with anti-p k antibodies (110). A small quantity of Gb 3 in various normal cells and in normal tissues may be cryptic.
Modification of Blood Group ABH, Ii, P, and Lewis Antigens in Human Cancer
Blood group antigens are the major allogeneic antigens in humans, and their presence not only is limited in blood cells but also is found in various epithelial cells. Since most human cancers originate from epithelial cells, changes in blood group antigens are an important topic in human tumor immunology. Glycolipids constitute an essential part of blood group antigens present at the cell surface membranes (111). In human tumors, blood group antigens change in the same general direction as other glycosphingolipids do in tumors, i.e., incomplete synthesis and neosynthesis. The major blood group changes in human cancer are listed in table 7.
Deletion of A and B Determinants
The most frequent and remarkable change in blood group determinants associated with human cancer is the deletion of blood group A or B antigen since it was first observed by Oh-Uti (112) and Masamune and co-workers (113). Extensive studies on this phenomenon were also pioneered by Davidsohn and associates (114) using the erythrocyte-adsorption method, including Formalin-fixed tissue sections. These studies and several other earlier works were reviewed previously (116, 117).
The deletion of A and B antigens can also be found in premalignant dysplasia of oral epithelia (118) which is associated with disorganization of precursor structure (83) . Similarly, Feizi and associates (84) observed that A/H antigens in secretors and I-antigen (Ma) in nonsecretors were lost in the mucosae of patients with intestinal metaplasia, some of which represent a precancerous state. These studies suggest strongly that the change of blood group A or B determinants can be useful in the detection of a premalignant stage.
To define the cause of these sensitive changes of A-and B-determinants, enzymatic studies on the synthesis of Aand B-determinants were performed. The results indicated that the A-transferase, which converts H-glycolipid to Aglycolipid, decreased significantly in tumors as compared with normal mucosa from the same individual (119).
Precursor Accumulation
The precursor structure for the type 2 chain blood group ABH antigen is represented by Ii structure (111, 120), although Ii structure can also be regarded as the precursor of sialosyl derivative (111, 121). An incomplete synthesis of the blood group ABH antigens or sialosyl derivative may result in accumulation of Ii structure. Simmons and Perlmann (122) first described the presence ofl-specific determinant in CEA and assumed that CEA may represent incomplete blood group antigens. Later studies (123) previously (116, 117). An A-like glycolipid with an obscure reactivity was isolated from a tumor of a host with blood type B and was identified as a Cer heptasaccharide with difucosylated A structure (134) . More recently, the presence of blood group A glycolipids with a clear A activity was demonstrated in a few cases of cancer from blood group 0 individuals (55, 101) . In an extensive study, Taketomi and associates (101) demonstrated a clear blood group A activity in the purified fucolipid fraction isolated from two cases of gastric cancer of blood group 0 patients. An A-like glycolipid showing a clear inhibition of A-hemagglutination was isolated from a case of hepatocarcinoma of a patient with blood group 0 (55). The glycolipid had no Forssman activity, showed a single spot on TLC, and was degraded by hog liver a-N-acetylgalactosaminidase. Direct probe mass spectrometry of the fraction after permethylation indicated the presence of a sequence GaINAca--+Hex--+HexN--+R but the absence of the usual A-determinant with a fucosyl residue. The tissue of this tumor also contained Forssman determinant in a short carbohydrate chain (table 4) . Human adenocarcinoma may produce an unusual aGalNAc transferase' with less restricted substrate specificity so that GalNAc residue could be added to the unusual structure (text- fig. 2 ).
Forssman antigen:
Immunologic distinction between A-like and Forssman antigens was difficult in early studies until the Forssman antigen was identified as glycolipid and its structure was established. Although considerable interest has been aroused for a possible role as a human tumor antigen suggested by early studies (59, 126) , it is premature to draw any conclusion. The presence of Forssman antigen in a case of biliary carcinoma was reported by Kawanami (126) , although normal tissue of this case was not examined. Subsequently, Forssman glycolipid of tumor tissue was compared with its adjacent normal tissue (59, 135) . Although normal human erythrocytes do not contain Forssman antigen, tissues of some populations (20-30% of gastrointestinal mucosa) contain relatively high levels of Forssman glycolipid (5 JLg/g wet tissue), while normal tissue of most of the human population had undetectable levels of Forssman glycolipid. Some gastric or colon tumors contain a much higher level (10 JLg/g wet tissue) of Forssman glycolipid derived from Forssman-negative tissue (59) . Many lung cancers, irrespective of their type, contained Forssman glycolipid, although the level was much lower than that for gastrointestinal tumor (6-25/Lg/1O g wet tissue). In contrast, the level of the antigen in normal adult lung was as low as 0.3 JLg/lO g tissue, although normal lung had almost the same level of enzyme for Forssman synthesis as in lung cancer. However, an isoantigenic property of Forssman in human tissues can be supported by a clear distinction of human populations in anti-Forssman titer of their sera.
The majority (70-80% of human sera) showed a significant level of anti-Forssman antibody as determined by Forssman liposome lysis, whereas the minority (20-30%) showed a very low, or undetectable, level of anti-Forssman antibody (136) , and the distribution of anti-Forssman level was altered significantly in sera of tumor patients.
PP1 antigen: Another striking example of the presence of incompatible blood group antigen in gastric cancer came from the work of Levine and associates (56, 57) . In 1951, Levine et al. (56) reported the case of a 66-year-old woman who had gastric adenocarcinoma. Her serum contained an agglutinin termed "anti-Tj"," which reacted with random populations of human erythrocytes. In desperation, she was given a 25-ml trial iv injection of 0 blood before surgery.
She had an immediate, severe reaction; but as a result, her anti-Tj" titer increased from 8 to 512. A few days later, surgery was performed without further blood transfusion. The patient survived for 22 years and died of brain hemorrhage without any obvious sign of metastasis. The anti-Tj" serum has now been identified as anti-PIppk specificities.
The patient obviously belonged to the rare genotype pp.
Recent analysis of her tumor glycolipid and glycoprotein has shown that the major glycolipid was identified as /3-GalNAc attached to paragloboside, whose terminal structure was identical as that of the P-antigen (globoside). A neutral glycolipid with PI activity was also demonstrated (58) . Thus the glycolipid alteration in this tumor of a rare pp genotype may involve neosynthesis of incompatible blood group PI and enhanced synthesis of P-like antigen as shown in text-figure 2.
DEVELOPMENTALLY REGULATED GLYCOLIPID MARKERS AND THEIR ANACHRONISTIC EXPRES-SION IN TUMORS
Some, if not all, of the aberrant expression of glycolipids in tumor cells that have been discussed in the foregoing sections may represent glycolipid profiles also present at early stages of development and differentiation. This concept has been well established in studies of the isozyme pattern (3) and cellular antigenicity (4) of embryo tissues in general. The orderly appearance or disappearance of carbohydrate markers during the process of ontogeny has been detected by various antibodies directed to blood group ABH (137), Forssman (138, 139) , blood group Ii (140), globoside (139) , and unidentified antigen(s) of embryonal carcinoma cells, F9 (141,142), and TerC (143) . The changes in carbohydrate structure of the early embryo and during the processes of hematopoiesis and epitheliogenesis will be discussed jointly with the carbohydrate expression in tumors.
Early Embryo and Teratocarcinoma
A common structure shared between undifferentiated teratocarcinoma cells and preimplantation early embryo has been detected by the common reactivity of these cells to the same antisera. Antisera to embryonal carcinoma cells, i.e., stem cells of teratocarcinoma, are capable of reacting with certain surface molecules of early mouse embryo. A syngeneic antiserum to F9 cells allowed detection of a surface structure of mouse embryo related to the Tit locus (144), and a rabbit antiserum to F9 cells was capable of detecting a specific surface structure present in preimplantation embryo, while the masking of this surface structure by Fab fragments blocks the compaction of morula, thus preventing development of morula to blastocyte (145) . Although biochemical properties ofF9 antigen(s) are still unknown, these early studies aroused considerable interest in this area, and consequently the monoclonal antibody approach has been applied in analysis of early embryo and teratocarcinoma. Thus expression of each carbohydrate chain is highly dependent on the specific stage of development in preimplantation mouse embryo as shown in text-figure 3. For instance, the monoclonal antibody, "SSEA-l ", prepared by immunization of mice with the F9 embryonal carcinoma cells, is expressed maximally at morula (146) . Upon differentiation of F9 cells and during the development of mouse embryo, SSEA-l expression declined and was limited to the germ layer and organ anlage (147) . The reactivity of SSEA-l antibody was inhibited by lacto-N-fucopentaose III, indicating the hapten structure recognized by the antibody is the al~3fucosylated type 2 chain (104). The complex fucosylated glycolipids with repeating N-acetyllactosamines having a terminal structure, Galpl~4[Fucal~3]GlcNAc (7), as well as polyfucosylared type 2 chain (7, 46) as shown in table 5, item B, were characterized as the antigen.
. Other antigens, Ii (140) SSEA-3 (148), Forssman (138, 139) , and globoside (139), showed a characteristic maximum expression at different stages. The SSEA-3 antibody was raised toward four-to eight-cell stage mouse embryos, showed a clear stage specificity in mouse embryogenesis, and reacted strongly with a number of undifferentiated human teratocarcinoma cells (148) . The antibody reacts with a set of globo-series structures present in teratocarcinoma cells. The new glycolipid Galpl~3GaINAcP13
Galal~4Galpl~4Glcpl~lCeris the best inhibitor for the anti-SSEA-3 antibody (Kannagi R, Levery SB, Hakomori S, Solter D, Knowles BR: Unpublished observation).
Markers in Hematopoiesis and Epitheliogenesis
The initial observation that fetal erythrocytes react with anti-i and that adult erythrocytes react with anti-I (149) led to extensive studies in the structural characterization of these antigens (121). These studies led to the conclusion that fetal erythrocytes have unbranched linear type 2 chain, in contrast to branched type 2 chain in adult erythrocytes (111, 120) . Blood group ABH determinants in fetal eryth- in which antigen i is expressed particularly at the endoderm (End) and is less strongly expressed at the ectoderm (EC). Composed from data in (46, 104, 139, 140, 146, 147, 148) . The structure for "SSEA-3" is unpublished data (Kannagi R, Levery SB, Hakomori S, Solter D, Knowles BB). -=negligible, +=weakly positive, ++=moderately positive, +++=strong, ±=partially positive. rocytes were carried by unbranched type 2 chain, whereas those in adult erythrocytes were carried by branched type 2 chain, offering a basis for ABH antigenic difference between fetal and adult erythrocytes (150) . Qualitative changes from i-to I-antigen on differentiation of human leukemia K562 cells (151) and in mouse myelogenous leukemia M I cells to macrophage-like cells were recently described. At the early stage of M I cell differentiation, the lacto-series synthesis was enhanced, resulting in the conversion of i-to I-antigen, and ganglio-series synthesis started to be supressed. Subsequently, globo-series synthesis was remarkably induced and resulted in accumulation ofGbs, accompanied by pk-antigen expression at the cell surface (152) . This model is important for understanding the glycolipid change observed in human leukemia cells. The major glycolipids in mature human blood cells are globo and lacto series, while in leukemia cells the presence of ganglio-series glycolipid is frequently observed, and in some cases loss or decrease of globo-series glycolipid is reported (115). The glycolipid composition of leukemia cells (24, 25) may reflect a block of sequential change of glycolipid synthesis during the normal differentiation of hematopoietic cells. The basal and parabasal layers of epithelia contain Lc3 and nLc4 as stained by their respective antibodies, whereas the spinous cell layers and flat epithelium cells were stained intensively by antibodies to HI (type 2 chain H) and Aantigens. This distribution pattern clearly indicates that chain elongation in type 2 lacto-series chain may proceed, associated with epithelium differentiation (130) . Similarly, crypt cell layers of intestinal epithelia contain LacCer, whereas villus cells contain GM3. Hence sialylation of LacCer takes place during the differentiation from crypt to villus cells (153) .
Anachronistic Expression of Glycolipid in Tumors
Various kinds of glycolipid changes in experimental animal and human cancer can be correlated with the anachronistic expression of glycolipids, possibly by a frozen program of differentiation and development. Experimental data to support this idea are still fragmentary; nevertheless, the model as shown in text-figure 4 can explain a great variety of glycolipid expressions in tumor cells.
A large variety of specific carbohydrate structures is expressed at different stages and at different loci of embryonic tissues and cells, as well as at different degrees of maturation in adult cell differentiation. These markers are maximally expressed at a specific stage; they disappear and reappear during ontogenesis. Some of them are continuously absent even after development of each cell. Disappearance or reappearance of a specific carbohydrate chain may be essentially based on an epigenetic repression or derepression of a regulatory gene. Isogenic or allogenic antigens (e.g., blood group antigens) behave in the same way. Each carbohydrate chain at the surface of adult cells in specific tissue must have its own history ofdevelopment and differentiation. A certain carbohydrate chain (e.g., chain A, in text- fig. 4 ) is expressed maximally at the morula to the early blastocyte stage, disappears later, and then is largely continuously suppressed in adult tissues with the exception of germinating cells. Such JNCI, VOL. 71, NO.2, an example can be seen in SSEA-l (147) . Other examples are further explained in the legend for text-figure 4.
Individual cells in adult tissue have different histories of carbohydrate expression in their development and differentiation. When cells are oncogenically transformed and eventually grow tumors, many carbohydrate chains in tumor cells display retrogenetic expression of their structures. Tumor A would display the carbohydrate chain A through its retrogenesis, and the carbohydrate chain B in tumor B is lost because of its retrogenesis to a certain point of development where chain B was not expressed. In contrast, tumor C would express carbohydrate chain continuously, for example.
Anachronism of glycolipid expression may reflect the failure of cell recognition and the loss of proliferation control through cell surface glycolipids in tumors. A large variation in carbohydrate changes in tumors can also be explained by this model. Anachronistic expression of tumor glycolipids may alter during tumor development, since retrogenesis may not operate under strict fidelity.
FACTORS AFFECTING GLYCOLIPID EXPRESSION AT THE CELL SURFACE
The reactivity of glycolipids at the cell surface with antibodies, lectins, and enzymes is governed by several factors, which are listed in table 8. These factors are mutually influential, and overall expression of glycolipids is controlled by highly complex mechanisms.
Glycolipid Concentration at the Cell Surface Membrane
The chemical concentration of glycolipids is the primary factor in determining the reactivity of glycolipids at the cell surface for some types of cells. For example, Gb3 in Burkitt's lymphoma and Gg3 in human melanoma have a hundredtimes higher concentration than in normal cells (6, 38, 41) . Small quantities of Gb 3 in human erythrocytes and in hamster fibroblasts were not reactive with anti-Gbs antibodies (110). Possibly, there is a threshold value for immunologic expression of cellular glycolipids, and the reactivity with antibody could be controlled by an "all-or-none" phenomenon.
In other types of cells, however, the reactivity of the major glycolipids to their antibodies is highly restricted due to their "crypticity," as described below.
Crypticity of Glycolipid Antigens at the Cell Surface
Some glycolipids are chemically present in considerable quantity but are immunologically poorly detectable, whereas other glycolipids present in relatively small quantity are conspicuous by immunologic methods, such as immunofluorescent staining. Glycolipid expression depends greatly on the degree of exposure at the cell surface, and the phenomenon is referred to as crypticity of glycolipids.
A restricted expression of Gb4 in human erythrocytes (154) and NIL cells (53) and that of GM3 in BHK cells (18) has been described, although these glycolipids are the major component in each type of cell. ===;========:l-====:J__~:=3~.c----dc
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TEXT-FIGURE 4.-An idealized version of stage-dependent expression of various carbohydrate chains during ontogenic process and retrogenetic expression of these structures in individual tumors. A large variety of specific carbohydrates bound to lipids (glycolipids) or to proteins (glycoproteins) is expressed at different stages and different loci of embryonic cells and tissues. They are maximally expressed at a specific stage of ontogenesis and they disappear, reappear, or are continuously absent during development. Intensity of expression is shown by density of dots.
• , tumors expressed; 0, tumors not expressed. Each carbohydrate chain in the left-hand column showed different stage specificities at different tissues during the process of ontogenesis. Stage of maximum expression of some carbohydrates in preimplantation embryo and that of other structures in postimplantation embryo are based on some experimental data in mice, except A and B antigen (AB) in humans. No data on preimplantation embryo of humans is available. A similar type of expression with different maximum stage of development is expected in humans since a differentiation-dependent change of carbohydrate antigens in human teratocarcinoma is different from that in mouse teratocarcinoma. The X-structure is assumed to be maximally expressed at blastocyte or later stage, to decline on further development, and to be reexpressed at various organ anlages and germ layers, but its expression is limited in later stages and in adult tissues (A). Globo series structures, including Forssman, may be expressed at the very early embryo, may decline later, and are limited in various tissues and organs (B). Blood group AB antigens are expressed in postimplantation embryos at the first trimester. Antigens declined later during the process of morphogenesis in various organs and reappeared after embryogenesis was completed (C). Sialosyl (sialyl) Lea or poly-X-structures are essentially absent in developed tissue but are present in a certain stage of embryo (D). Thus each specific structure has its own history, showing characteristic maximum expression at a certain stage of ontogenesis. In each clone of transformed cells, its carbohydrate patterns were the same as those found at a certain stage of embryo, i.e., a frozen pattern of ontogenesis. For instance, expression of A is greatly enhanced in tumor A (T A) since retrogenesis occurs to the stage where A is expressed maximally (route a). Carbohydrate chain B in tumor B (TB) that could be greatly enhanced for its expression is similar to a stage when chain B is at its maximum (route b). Alternatively, its expression is completely deleted for its retrogenesis occurs to a blank stage (route b'). Carbohydrate chain C would be deleted in tumor C (Tc) ifretrogenesis was set at the stage where chain C was suppressed (route c). Expression in tumor D (TD) of tumor-specific carbohydrate chain D (e.g., sialyl Lea and poly-X), which is almost absent in adult tissue, is due to its retrogenesis (route d) at a certain stage of development. A large variation in carbohydrate expression in various tumors can be explained by this hypothetical scheme. The discrepancy between immunologic reactivity and chemical quantity of glycolipids is also obvious in some transformed cells. For instance, the expression of Gb, (Forssman antigen) is enhanced much more in py-transformed NIL cells than in parental NIL cells as detected by immunologic techniques, but the chemical amount of Forssman glycolipid in transformed cells is less than in parental cells (163) . Similarly, the expression of GM 3 or Gb4 in py-transformed BHK or NIL cells is greater than in nontransformed progenitor cells, although nontransformed cells contain much more GM 3 or Gb 4 (18, 53).
The crypticity of glycolipids is controlled by several complex factors, such as coexisting proteins, glycolipids, and Cer composition, which will be discussed.
Coexisting Proteins and Glycolipids, in Membranes, Affecting the Reactivity of a Glycolipid Antigen
Membrane Proteins
A few lines of evidence show that membrane proteins affect the immunologic expression of glycolipid antigens. The reactivity of globoside in human erythrocytes (154) Certain antigenic determinants, such as blood group ABH and X, are carried by polylactosaminyl core structures with different chain lengths. In general, greater activity was observed with longer chain carrier than with shorter chain carrier. This was clearly observed by liposome lysis test with SSEA-l antigens of erythrocytes and their antibodies (7) . Another factor controlling glycolipid reactivity at the cell surface is the valency of the determinant group in glycolipid due to the degree of branching. The reactivity of two determinants carried by a branched structure is much greater than that of the same determinant carried by unthat of GM I in mouse lymphocytes (155) were greatly enhanced when the cells were treated with proteases. The reactivity of Gb4 and Gb a with Gal oxidase at the NIL cell surface was greatly enhanced by treating cells with a low concentration of concanavalin A or Ricinus communis lectin (162) . Similarly, lO-times enhancement of Gb, reactivity with Gal oxidase at the mouse lymphoma cell surface was found to be induced by sialidase, although the chemical quantity of Gba was unchanged and although Gb a was not sialylated in a sialidase-susceptible form (164) . These results indicate that protease, sialidase, and lectins may induce reorganization of membrane protein and may cause the enhanced exposure of membrane glycolipids (text- fig. 5: c,  d ). The effect of sialidase on Gb, exposure, however, can be interpreted alternatively (see below).
The effects of membrane proteins seem to differ in nontransformed cells from those of transformed cells. The reactivity ofGMa in nontransformed cells was greatly enhanced, but that in transformed cells was less affected by protease treatment (18, 53, 162) .
Membrane G/ycolipids
Another line of observations suggests that the reactivity of a glycolipid at the cell surface could be affected by interaction with a second or third glycolipid. According to (165) glycolipids many cluster in cell membranes because the physicochemical properties of Cer are different from diacylphospholipids. The effect of one glycolipid on antigenicity of another glycolipid was observed in vitro, in that the antigenicity of HI glycolipids was completely inhibited by the copresence of a large amount of globoside in membranes (157) . Similarly, the antigenicity of' Cg, was masked by the copresence of a longer glycolipid such as Gg4, GMIa, or GMIb on solid-phase radioimmunoassay. The suppression of Gga activity was stoichiometric (Kannagi R, Cochran N, Hakomori S: Unpublished results). Analogous inhibition of Gga activity has been suggested at the cell surface; for instance, mouse lymphoma with low reactivity to anti-Ggs contains much higher quantities of GM Ib and Gg4 than does the same lymphoma with high reactivity. Thus GMIb may mask Gga in mouse lymphoma, and the reactivity of Gga to its monoclonal antibody may be inhibited by the presence ofGM lb, as illustrated in text- figure 5 (a, b) . A simplification of glycolipids associated with incomplete synthesis may result in enhanced reactivity of the precursor short-chain glycolipid, even if chemical quantity of the antigenic glycolipid is not altered.
Cholesterol
Another important factor for determining reactivity of membrane antigens is the cholesterol content. Agglutinability of human erythrocytes to anti-I (Ma, Step, K) antibodies was enhanced by cholesterol enrichment and inhibited by cholesterol depletion (166) . Shinitzky and associates (167) observed that tumor immunogenicity can be effectively induced by incorporation of cholesterol by treating cells with cholesteryl hemisuccinate. They imply that a latent tumor antigen can become accessible to the immune competent system upon rigidification of the membrane lipid layer.
JNCI, VOL. 71, NO.2, branched structures by an order of 10 3 . Such a structure is called "monogamous bivalency" (168) . The reactivity of umbilical-cord erythrocytes to antilactosamine antibody is much less than that of adult erythrocytes (159) . A weak reactivity of cord erythrocytes to anti-A or anti-B IgG antibodies in antiglobulin tests has been known and is now correlated with the lack of bivalent monogamous A or B determinants in infant erythrocytes (158) .
Effect of Subtle Differences in Structure of Carrier Carbohydrate Chain
Since the core structure can affect the entire tertiary structure of glycolipid antigens, it is reasonable to assume that subtle changes in the core structure may modify antigenic expression of the determinants. Monoclonal anti-H antibodies recently established (159) react only with Hstructure carried by type 2 chain (Fuca 1_2Gal,8 1-4G1cNAc) but not by type 1 chain H (Fucal-2Gal,81-3G1cNAc) or by ganglio series H (Fucal-2Gal,81-3Gal-NAc). In fact, the type 1 chain H above is not H but is now identified as Lee (156) . The A-determinant (GaINAcal_ 3[Fucal-2]Gal) carried by type 1 chain is distinguished from that carried by type 2 chain by the monoclonal antibody to the "type 1 chain A" (Abe K, Hakomori S: Unpublished result).
Cer Composition
Differences in Cer composition will affect the organizational state of glycolipids in cell surface membranes that modify the glycolipid reactivity to their antibodies and ligands. The two acyl chains in Cer are almost equal length in glycolipids, having short-chain fatty acids (C 14:0 to CI8:0), whereas two acyl chains in glycolipids having longer fatty acids (C22:0, C22: 1, C24:0, C24: 1) are very unbalanced; one of them is approximately 1.2-1.5 times longer than the other. This causes organizational and stability differences of the glycolipids in the lipid bilayer (169, 170) . The arrangement of glycolipid antigens having hydroxylated Cer in either a-hydroxy fatty acids or 3-hydroxysphinganine is much different in glycolipid antigens without hydroxyl function at the Cer. In normal tissues and cells the Cer composition is strictly regulated and kept constant. A regularity is also found between Cer composition and carbohydrate structure. Brain GalCer and sulfatide are characterized by a long-chain fatty acid and its a-hydroxylated species of a long-chain fatty acid, which, in contrast to gangliosides, have almost exclusively C18:0 fatty acids. In human erythrocytes, both short-chain and long-chain fatty acids are present in nearly equal quantity in GlcCer and LacCer. However, only long-chain species predominate in Gb3, Gb4, and other higher glycolipids (110). Glycolipids with X-determinants and sialosyloz-e-f gangliosides contain only C16:0 fatty acids in a striking contrast to blood group ABH antigens and sialosyla2_3 gangliosides containing long-chain fatty acids (160) . In malignant cells and tumors, this normal regularity between Cer composition and sugar structure is disarranged. Glycolipids with X-structure or sialosyl a2_6 gangliosides from tumor tissue had Cer having a-hydroxy fatty acids, long-chain fatty acids, and 3-
Glycolipid Tumor Differentiation Markers 245
hydroxysphinganine. Such a discordance may result in a drastic change in glycolipid stability in lipid bilayer and may enhance glycolipid antigenicity. GD a ganglioside in human melanoma was characterized as having Cer with long-chain fatty acids in a striking contrast to GD a of normal brain having Cer with short-chain fatty acids (6) . A close correlation between antigenicity of Gg, in mouse lymphoma L-5178Y and their Cer composition was recently studied. A greater antigenicity was found to correlate with the amount of a-hydroxy C16:0 fatty acid. It is suggested that the glycolipid becomes more exposed when Cer has a-hydroxy fatty acid (161). The reactivity and immunogenicity of liposomes containing FucCer having long-chain fatty acids and a-hydroxy fatty acids were significantly higher than those of liposomes containing short-chain fatty acids (192) .
Factors Arising From the Nature of Ligands and Immunoglobulin Class
The reactivity of membrane glycolipids depends greatly on the nature of ligands and immunoglobulin class. Recent studies of early embryo with anti-Forssman antibodies clearly indicated that polyclonal antibodies showed much stronger reactivity than did monoclonal IgM antibody (139) . Monoclonal IgG3 directed to Gga completely suppressed the tumor growth of mouse lymphoma L5178, whereas IgM antibody directed to the same antigen did not suppress the tumor growth (53) . One monoclonal antibody with specific reactivity to X-hapten (LeX) reacts very well with glycolipids having short core carbohydrate chains, whereas other monoclonal antibodies with the same specificity preferentially react with glycolipids having longer core carbohydrate chains (7, 46) .
Besides immunoglobulins, lectins and Gal oxidase are also used for the detection of glycolipid antigens. There is a significant difference between the reactivity of a glycolipid to lectins and antibodies. Gba (pk antigen) in human erythrocytes is cryptic to IgM antibodies (110), but the reactivity of the same glycolipid with specific lectins from Escherichia coli pili is easily detectable (171) . Rabbit antibodies directed to Gb 4 showed minimum reactivity with human erythrocytes, although Gb4 is the major component of human erythrocytes (154) , but Gal oxidase reacts extensively with Gb4 at the cell surface and could label Gb4 with subsequent reduction by tritiated sodium borohydride (53) . Thus the precise assessment of glycolipid crypticity requires specific information on the properties of the ligands used for detection of the antigens.
FUNCTIONAL CHANGE OF PLASMA MEMBRANES AS RELATED TO GLYCOLIPID CHANGES IN CANCER
Why do tumor cells change their carbohydrate chain in glycolipids as well as in glycoproteins? The question is closely related to the general basic function of carbohydrate chains at the cell surface. One trend of studies is toward understanding how aberrant carbohydrate structures, including their anachronism, may cause failure of cell-to-cell recognition among cells. The absence of contact response in glycolipid synthesis (12, 17-19, 63) may reflect the failure in cell recognition.
An aberrant profile of cell surface glycolipid, which occurs as a consequence of blocked synthesis or neosynthesis, may cause a failure of cellular interaction through a carbohydrate-recognizing protein (cognin) at the surface of counterpart cells, although cognin is unchanged on transformation. The cognin could be a glycosyl transferase (172, 173) , hydrolase (174, 175) , or animal lectin (176) . Although startling discoveries of specific cell surface receptors in liver cells for serum glycoproteins and in certain fibroblasts for lyzosomal enzymes have been made and although the mechanism for receptor-mediated endocytosis has been greatly advanced in recent years [for review (177) ], the knowledge has not been applied to a possible role of carbohydrate-cognin interaction in oncogenesis. One phase of cell recognition involves cell attachment through adhesion matrix (178), adhesion plaque (179), or detergent insoluble matrix (180) . Recently, much attention has been focused on molecular mechanisms associated with these structures, since a loss of cell adhesion is associated with oncogenic transformation, accumulation of src gene product (P60 srC ) at the cytoplasmic loci of focal adhesion plaques (181) , and phosphorylation of tyrosine group of vinculin at the adhesion site (182) . A set of membrane proteins (140K, 170K, 250K) and fibronectin and cytoskeletal components vinculin and actinin are cooperating in a highly organized fashion (180, 183) . Although gangliosides are not considered as functional components of adhesion plaque, they could play important roles in cell adhesion since 1) gangliosides are present in substrate attachment matrix as well as in detergent-insoluble matrix (184-186) and 2) gangliosides can inhibit cell adhesion on fibronectin-coated substrate (187) as well as on other substrates nonspecifically (174) .
However, certain gangliosides, such as GM3, which is ubiquitously distributed in a large variety of cells and which is deleted or reduced greatly on transformation, may have a basic function in regulation of cell growth. Recent studies on cell growth regulation in chemically defined medium revealed that GM 3 may regulate the function of the receptor for fibroblast growth factor (89) . Similarly, GM1 in other types of cells may regulate receptor function for plateletderived growth factor and perhaps other growth factor receptors as well (Bremer E, Bowen-Pope D, Ross R, Hakomori S: Unpublished data).
Possible involvement of gangliosides in two basic cellular functions, 1) cell adhesion and recognition and 2) regulation and maintenance of growth factor receptor function, would immediately suggest that defective synthesis of these gangliosides may cause loss of growth control and anchoragedependent cell proliferation, which are the most common denominators of oncogenesis.
DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS OF GLYCOLIPID CHANGES ASSOCIATED WITH CANCER
Whatever the function of glycolipid changes in tumor cells may be, they can be applied in diagnosis of human cancer and precancerous states. A sensitive radioimmunoassay was introduced recently by Koscielak and his associates (188) using radiolabeled lactosylsphingosine-bovine serum albumin conjugate. The method was designed to determine the serum antibody level directed to lactosylsphingosine, JNCI, VOL. 71, NO.2, AUGUST 1983 and the level was claimed to be well correlated with development of cancer. These findings would support a view of classical study by Rapport and Graf (189) that LacCer is immunogenic in human tumor membranes. The monoclonal antibody N-19-9 directed to sialosyl Lea structure (51), prepared by Koprowski et al. (94) , was essentially specific to colorectal carcinoma. Its binding to tumor cells can be inhibited by sera from patients with various types of cancers (52) , and the phenomenon was claimed to be useful in diagnosis of human cancer. The change of anti-Forssman antibody titer determined by liposome lysis assay was claimed to be correlated with development of human cancer (136) .
Specific glycolipid markers and their specific glycosyl transferases are theoretically useful for diagnosis of precancerous states as applied to histologic examination. The deletion of A-or B-antigen and the appearance of type 2 chain H or N-acetyllactosaminyl structure (Gal/11-4GlcNAc/11-R) as detected by respective monoclonal antibodies have been applied to diagnosis of precancerous dysplasia of buccal mucosa (82) . An accumulation of I (Ma) antigen in premalignant intestinal metaplasia of gastric mucosa (84) will be useful if properly applied in clinical gastric biopsy. The appearance of Forssman antigen and Alike antigen may have less diagnostic value since the quantity of the antigen in tumors is very low. However, there are a few exceptional cases in which a large amount of these antigens that may be important targets for therapeutic applications are accumulated. The most exciting marker for human cancer could be difucosylated, trifucosylated, or polyfucosylated type 2 chain glycolipids that accumulate in a large variety of human cancers, as was discussed. The antibodies that do not cross-react with X but are specific to such difucosylated-to-polyfucosylated structures are of potential diagnostic and therapeutic value.
A classical report by Levine et al. (56) and a more recent case report by Kabat and associates (125) strongly indicate that immunotherapy of human cancer is possible if the right antibodies directed to the right carbohydrate markers are chosen. A successful application of immunotherapy by monoclonal antibody directed to a glycolipid antigen was performed in a mouse model with the use of mouse lymphoma L5178 with the monoclonal IgG3 antibody directed to the specific tumor marker Gg3 (54) . According to these studies as well as to a recent report by Herlyn and Koprowski (190) , only a specific subclass of IgG, which may interact and activate macrophages, but not IgM class, is effective in suppressing tumor growth. The immunoglobulin induced by transfusion of unmatched blood in a classical case of Levine et al. (56) was also IgG class.
Specific delivery of chemotherapeutic drugs by antibody-drug conjugates directed to glycolipid targets through biotinyl drug, biotinyl antibodies, and avidin has been recently developed (191) . We anticipate that the combination of proper monoclonal antibody and specific delivery of drugs to tumor cells will be a crucial approach in control of human cancer in the near future. There is, however, a major drawback inherent in these approaches, that is, the heterogeneity of glycolipid expression among tumor cells. In our model experiment (54) L5178Y tumors, arising after immunotherapy with small doses of IgG3 antibody, contained a very low quantity of Gg3, although a homogeneous highexpresser clone was inoculated. This model suggests that heterogeneity of glycolipid expression is created in vivo during interaction with antibodies. To avoid such a situation, a well-planned therapy with multiple target molecules is highly desirable. One major advantage of glycolipid markers is that they are shared with multiple types of tumors. It is important to deepen and extend our knowledge of structural profiles of glycolipids in each type of tumor at different stages of development, since our knowledge on this topic is still highly fragmentary.
CONCLUSIONS AND PERSPECTIVES
Glycolipids of cell surface membranes alter their chemical composition and organization upon oncogenic transformation in vitro and in tumors in vivo. The changes can be observed in tumors transformed by DNA and RNA tumor viruses, chemical carcinogens, and in spontaneous tumors, including human cancer. Four types of changes-blocked synthesis, neosynthesis, altered contact response, and changes of organization-have been observed. The blocked synthesis is due to a suppressed (or repressed) glycosyl transferase, and the neosynthesis is caused by activation (or derepression) of an unusual enzyme with less restricted substrate specificity. Some of these changes are caused perhaps as a consequence of transforming gene activation, as typically observed in virally transformed cells. The mechanism of activation (derepression) and repression of glycosyl transferases associated with transforming gene activation will be an important topic.
Some, if not all, glycolipid changes in tumors are probably due to a frozen program of differentiation and development, since several anachronistic expressions of glycolipid synthesis have been observed. A correlation between a frozen program of development and transforming gene activation is an important link for understanding the biologic significance of transforming genes. The question of why cells alter their glycolipid profile on oncogenic transformation is a basic one involving functions of cell surface carbohydrates. Our knowledge of the basic function of glycolipids is extremely fragmentary. Two important ideas, one for cell recognition and the other for regulation of membrane receptor function, have been discussed. Further extensive studies in these two areas will obviously deepen our knowledge of how glycolipid changes are coupled with the mechanism of oncogenesis and differentiation.
Whatever the mechanism and biologic significance of glycolipid changes, neoglycolipids accumulated in a specific type of tumor can be an excellent target for diagnosis and therapy of human cancer in the immediate future, as we have discussed. An optimistic way for this goal has been opened by monoclonal antibody approach and technology for glycolipid characterization; however, there are drawbacks in this approach, which we have also discussed. If a regulatory mechanism of glycolipid synthesis would be aberrant in cancer, we are in the position to isolate genes and to correct a defective enzyme. Genetic technology for glycolipid synthesis and degradation will give us important clues for control of cancer.
